A detailed history of Hillsdale Investment Management Inc. transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Hillsdale Investment Management Inc. holds 830 shares of BCRX stock, worth $7,146. This represents 0.0% of its overall portfolio holdings.

Number of Shares
830
Holding current value
$7,146
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$6.41 - $8.69 $5,320 - $7,212
830 New
830 $6,000
Q3 2020

Nov 13, 2020

SELL
$3.43 - $5.53 $589,960 - $951,160
-172,000 Closed
0 $0
Q2 2020

Aug 11, 2020

BUY
$1.9 - $5.61 $326,800 - $964,920
172,000 New
172,000 $820,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.6B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Hillsdale Investment Management Inc. Portfolio

Follow Hillsdale Investment Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hillsdale Investment Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hillsdale Investment Management Inc. with notifications on news.